King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. It offers branded prescription pharmaceuticals, which include neuroscience products, such as Skelaxin, Flector Patch, Avinza, and Embeda; hospital products, including Thrombin-JMI; and legacy products consisting of Levoxyl, Bicillin, Altace, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. The companys animal health business focuses on medicated feed additives and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets. King Pharmaceuticals also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. The company also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. King Pharmaceuticals distributes its branded pharmaceutical products through wholesale pharmaceutical distributors, as well as animal health products through sales force. The company was founded in 1993 and is based in Bristol, Tennessee.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [10/31/2025 12:43 PDT] King Pharmaceuticals Inc. (NYSE:KG), Down By 100% ($23.44) From $23.44 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [10/30/2025 07:03 PDT] KG Expected to Trade Down After Bearish Patterns Develop
• [10/23/2025 07:14 PDT] KG Expected to Trade Up After Bullish Patterns Develop
• [10/02/2025 15:33 PDT] King Pharmaceuticals Inc. (NYSE:KG), Down By 100% ($28.33) From $28.33 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [09/25/2025 07:07 PDT] KG Expected to Trade Down After Bearish Patterns Develop
• [09/12/2025 07:15 PDT] KG Expected to Trade Up After Bullish Patterns Develop
• [09/11/2025 07:26 PDT] KG Expected to Trade Up After Bullish Patterns Develop